Effect of Bisphosphonates on the Levels of Rankl and Opg in Gingival Crevicular Fluid of Patients With Periodontal Disease and Post-menopausal Osteoporosis.
The Receptor activator of nuclear factor-kappa B ligand (RANKL)/RANK/Osteoprotegerine (OPG) system has been proposed as essential for osteoclast biology and identified as key part in regulating the physiology and pathology of the skeletal system. The study of the RANKL/RANK/OPG system has increased the understanding of the mechanisms involved in the bone remodeling process, especially in postmenopausal osteoporosis and periodontal disease. Bisphosphonates have become the mainstay of the treatment and prevention of post-menopausal osteoporosis. They inhibit the formation and dissolution of calcium phosphate crystals in bone and also osteoclasts, thus reducing bone turnover.Current investigations relate osteoporosis with the appearance and progression of periodontal disease. Although the etiology of both is different, the bone loss present in both shares several characteristics. Thus, therapy used for osteoporosis can be considered of value in the treatment of periodontal disease. The aim of this study was to evaluate the levels of RANKL, OPG and their relationship in gingival crevicular fluid (GCF) in patients with periodontal disease and postmenopausal osteoporosis/ osteopenia in relation to consumption of bisphosphonates. We studied 66 periodontal active sites obtained from 17 post- menopausal women patients aged between 45-70 years old with osteoporosis/osteopenia and periodontal disease. GCF samples were collected using sterile filter paper strips. To determine the concentration of RANKL and OPG, a commercial ELISA assay was used. The values of RANKL, OPG and their ratio (RANKL/ OPG) were compared with Mann-Whitney U Test. The values of RANKL, OPG and their ratio obtained in patients with osteoporosis/osteopenia and periodontal disease with or without bisphosphonates treatment showed no differences. Bisphosphonates do not alter the concentration of RANKL and OPG and their ratio in the GCF of patients with osteoporosis/ osteopenia and periodontal disease, probably because these cytokines may not be the main target of bisphosphonates to inhibit bone resorption in periodontal disease.
Periodontology Department, School of Dentistry, National University of Córdoba, Córdoba, Argentina. eugenia.verde@unc.edu.ar.
María E
ME
Verde
Center of Biochemistry and Immunology Research. School of Chemistry Sciences. National University of Córdoba, Córdoba, Argentina.
Daniela
D
Bermejo
Center of Biochemistry and Immunology Research. School of Chemistry Sciences. National University of Córdoba, Córdoba, Argentina.
Adriana
A
Gruppi
Periodontology Department, School of Dentistry, National University of Córdoba, Córdoba, Argentina.
Miriam
M
Grenón
D004164:Diphosphonates; D005260:Female; D005883:Gingival Crevicular Fluid; D006801:Humans; D015663:Osteoporosis, Postmenopausal; D053244:Osteoprotegerin; D010510:Periodontal Diseases
D004164:Diphosphonates; D053244:Osteoprotegerin
OPG; RANKL; bifosfonatos; enfermedad periodontal; osteoporosis